Welcome everyone on this Monday morning to our update following our Type A meeting with the FDA on the call today. This morning, we have Andreas Norlin, Chief Scientific Officer, and myself, Magnus, co-founder and CEO of Ascelia Pharma. On this call, we will be making forward-looking statements regarding this brief update. We will start by having Andreas go through the key outcomes of the Type A meeting. After that, I will talk about how the outcome translates into our strategic priorities with Orviglance before opening up for questions. Andreas, please go ahead. Thank you, Magnus. So overall, we view the Type A meeting as an important and constructive step forward for Orviglance. So while the FDA maintains its position that additional clinical evidence will be required for approval, the meeting substantially reduced uncertainty around the product quality and clinical aspects of the Complete Response Letter. On the product quality side, we achieved a clear understanding of the FDA's expectations and reached alignment on the path forward and, importantly, on the clinical side. The discussion moved beyond the requirement of conducting a completely new clinical trial. The FDA acknowledged the medical need, the favorable safety profile, and the technical performance of Orviglance as a T1-enhancing contrast agent. But most importantly, the meeting identified an alternative approach that could potentially generate additional clinical evidence required for approval. As a result, we now have greater clarity, reduced regulatory uncertainty, and greater flexibility in evaluating the most efficient path toward U.S. approval than we had before the meeting. approval than we had before the meeting.
The first positive outcome from the meeting relates to product quality. FDA and Ascelia Pharma thoroughly discussed the issues raised in the CRL relating to specifications and analytical methods for the drug product, and alignment was reached on the proposed strategy to address the FDA observations. This is important because it removes a significant area of uncertainty. The regulatory expectations are now understood and implementation activities have already started. While work remains, we think the meeting established a clear and actionable path to resolve the product quality component of the Complete Response Letter. The most important outcome of the meeting was on the clinical and regulatory side. In the Complete Response Letter, FDA's recommendation was essentially to conduct a new clinical study with new patients. Following the discussions in the Type A meeting, the FDA confirmed that this remains one possible route. However, and very importantly, the agency also acknowledged an alternative approach. Specifically, FDA indicated that additional clinical evidence could potentially be generated through a new evaluation of the existing SPARKLE image database using a different primary endpoint than originally used. We view this as a significant and encouraging development, rather than having only a single path forward. Instead of relying on a completely new clinical study, there is now the possibility of leveraging the substantial clinical data that have already been generated. Additional work is still required, and our next step is to evaluate potential endpoints that could appropriately address FDA's concerns. And before any image reading process is initiated, alignment with the FDA on the selected endpoint would be obtained. So while the FDA continues to require additional clinical evidence, the meeting materially changed our understanding of how that evidence may potentially be generated. We believe that opening the possibility to use the existing SPARKLE database represents a meaningful opportunity and a substantially more favorable position than the original recommendation of conducting an entirely new clinical study. This is an opportunity we are now actively evaluating. To summarize, the key takeaway is that the meeting changed the conversation from requiring a new clinical study. Clinical studies required to. There may be more than one path to generate the clinical evidence needed for approval. Combined with the alignment achieved on product quality, we believe this represents an important reduction in regulatory uncertainty and a positive development for the Orviglance program in the US. So I will now give the word back to Magnus to talk about our strategic priorities for Orviglance.